Cargando…

Six and eight weeks injection frequencies of bevacizumab are non-inferior to the current four weeks injection frequency for quality of life in neovascular age-related macular degeneration: a randomized controlled trial

PURPOSE: Patients with neovascular age-related macular degeneration (nARMD) will not deteriorate on visual acuity and retinal thickness when treated with bevacizumab injection frequencies of 6 or 8 weeks compared to 4 weeks. This study aimed to investigate this non-inferiority in quality of life (Qo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Visser, Martijn S., Amarakoon, Sankha, Missotten, Tom, Timman, Reinier, Busschbach, Jan J. V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7686180/ https://www.ncbi.nlm.nih.gov/pubmed/32666333 http://dx.doi.org/10.1007/s11136-020-02580-9

Ejemplares similares

SF-6D utility values for the better- and worse-seeing eye for health states based on the Snellen equivalent in patients with age-related macular degeneration
por: Visser, Martijn S., et al.
Publicado: (2017)

Intravitreal bevacizumab has initial clinical benefit lasting eight weeks in eyes with neovascular age-related macular degeneration
por: Conrad, P William, et al.
Publicado: (2008)

Monthly Alternating Injections of Aflibercept and Bevacizumab for Neovascular Age-Related Macular Degeneration
por: Lee, Junyeop, et al.
Publicado: (2022)

Macular Hole following Intravitreal Bevacizumab Injection in Choroidal Neovascularization Caused by Age-Related Macular Degeneration
por: Moisseiev, Elad, et al.
Publicado: (2010)

Lamellar macular hole formation following intravitreal bevacizumab injection for choroidal neovascularization by age-related macular degeneration
por: Torabi, Hamidreza, et al.
Publicado: (2018)

Real-World Injection Frequency and Cost of Ranibizumab and Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema
por: Kiss, Szilárd, et al.
Publicado: (2020)

Regression of Iris Neovascularization after Subconjunctival Injection of Bevacizumab
por: Ryoo, Na Kyung, et al.
Publicado: (2013)

Ranibizumab Injection for Corneal Neovascularization Refractory to Bevacizumab Treatment
por: Ahn, Ye Jin, et al.
Publicado: (2014)

Intravitreal Expansile Gas and Bevacizumab Injection for Submacular Hemorrhage Due to Neovascular Age-related Macular Degeneration
por: Nourinia, Ramin, et al.
Publicado: (2010)

Multifocal Electroretinogram Findings after Intravitreal Bevacizumab Injection in Choroidal Neovascularization of Age-Related Macular Degeneration
por: Park, Joo Youn, et al.
Publicado: (2011)

Intravitreal injection of Bevacizumab in diabetic macular edema
por: Ateeq, Asim, et al.
Publicado: (2014)

Influence of unilateral intravitreal bevacizumab injection on the incidence of symptomatic choroidal neovascularization in the fellow eye in patients with neovascular age-related macular degeneration (Review)
por: Branisteanu, Daniel Constantin, et al.
Publicado: (2020)

Oral Doxycycline Reduces the Total Number of Intraocular Bevacizumab Injections Needed to Control Neovascular Age-related Macular Degeneration
por: MIRSHAHI, Ahmad, et al.
Publicado: (2017)

Study of the Effect of Injection Bevacizumab through Various Routes in Neovascular Glaucoma
por: Bhagat, Purvi R, et al.
Publicado: (2016)

Intrastromal Injection of Bevacizumab in the Management of Corneal Neovascularization: About 25 Eyes
por: Sarah, Belghmaidi, et al.
Publicado: (2016)

Twelve-week dosing with Aflibercept in the treatment of neovascular age-related macular degeneration
por: Garweg, Justus G
Publicado: (2019)

Macular Hole Formation after Intravitreal Injection of Bevacizumab for Diabetic Macular Edema
por: Lee, Yun Ji, et al.
Publicado: (2019)

Study of twice-weekly injections of Teriparatide by comparing efficacy with once-weekly injections in osteoporosis patients: the TWICE study
por: Sugimoto, T., et al.
Publicado: (2019)

Bevacizumab for CRVO Associated CME: Effect of Timing and Frequency of Injections on Final Visual Outcome
por: Pikkel, Joseph, et al.
Publicado: (2013)

Anterior segment changes following intravitreal bevacizumab injection for treatment of neovascular glaucoma
por: Canut, MI, et al.
Publicado: (2011)

A Case of Intravitreal Bevacizumab Injection for the Treatment of Choroidal Neovascularization in Angioid Streaks
por: Lee, Ji Woong, et al.
Publicado: (2011)

The Forty-Eight-Hour Week
Publicado: (1919)

Eight Weeks without Food
Publicado: (1891)

Small extracellular vesicle-loaded bevacizumab reduces the frequency of intravitreal injection required for diabetic retinopathy
por: Reddy, Shivakumar K, et al.
Publicado: (2023)

A very short version of the Visual Function Questionnaire (VFQ‐3oo7) for use as a routinely applied Patient‐Reported Outcome Measure
por: Visser, Martijn S., et al.
Publicado: (2020)

Effect of Posterior Subtenon Triamcinolone Acetonide Injection on Diabetic Macular Edema Refractory to Intravitreal Bevacizumab Injection
por: Kim, Min Woo, et al.
Publicado: (2016)

Characteristics of Macular Edema in Behcet Disease after Intravitreal Bevacizumab Injection
por: Ghassemi, Fariba, et al.
Publicado: (2017)

Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD
por: Avery, Robert L, et al.
Publicado: (2014)

Long-term outcomes of intravitreal injection of bevacizumab for choroidal neovascularization associated with choroidal osteoma
por: Yoshikawa, Tadanobu, et al.
Publicado: (2015)

Frequency and momentum tolerances at injection
por: Johnsen, Kjell
Publicado: (1953)

Decrease in Anti-VEGF Injections After Post-injection Endophthalmitis in Patients With Neovascular Age-Related Macular Degeneration
por: Binczyk, Natalia M., et al.
Publicado: (2023)

Comparing the Postpartum Quality of Life Between Six to Eight Weeks and Twelve to Fourteen Weeks After Delivery in Iran
por: Bahrami, Nosrat, et al.
Publicado: (2014)

A Forty-Eight Hours' Week
Publicado: (1920)

The Probationers' Forty-Eight-Hour Week
Publicado: (1920)

A Forty-Eight Hour Week
Publicado: (1919)

Concentration of Vascular Endothelial Growth Factor After Intracameral Bevacizumab Injection in Eyes With Neovascular Glaucoma
por: Lim, Tae Hoon, et al.
Publicado: (2009)

Long-Term Outcomes and Prognostic Factors of Trabeculectomy following Intraocular Bevacizumab Injection for Neovascular Glaucoma
por: Higashide, Tomomi, et al.
Publicado: (2015)

Successful regression of newly formed corneal neovascularization by subconjunctival injection of bevacizumab in patients with chemical burns
por: Peng, Wen-yan, et al.
Publicado: (2023)

Aqueous vascular endothelial growth factor and clinical outcomes correlation after single intravitreal injection of bevacizumab in patients with neovascular age-related macular degeneration
por: Cabral, Thiago, et al.
Publicado: (2017)

Intravitreal Bevacizumab versus Combined Bevacizumab and Triamcinolone Acetonide for Neovascular Age-Related Macular Degeneration
por: Riazi-Esfahani, Mohammad, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_sb5s4pbsaarone6bgpj2kgh6qd